From Interview #95
With Dr. Bernardo Perez-Villa
Dr. Bernardo Perez-Villa, Senior Innovations Engagement Partner at the Cleveland Clinic, shares grounded insights into the true drivers of successful innovation in healthcare. Drawing on his global background in biodesign and commercialization, he discusses the real-world challenges of bringing AI technologies from concept to clinic. From assessing unmet clinical needs to understanding payer dynamics and regulatory bottlenecks, Perez-Villa emphasizes frameworks that distinguish viable solutions from hype. Hosted by Dr. Sanjay Juneja, this conversation unpacks the realities of product-market fit, digital health business models, and how to responsibly scale innovation without compromising on patient safety or financial sustainability.
From Interview #94
With Emi Gal
How can artificial intelligence make full body MRI screening faster, more affordable, and more accurate? In this compelling interview, Ezra founder and CEO Emi Gal discusses how FDA-approved AI medical devices are transforming MRI scans into a powerful tool for early cancer detection. Gal outlines Ezra's three-tiered AI pipeline—enhancing image quality, assisting radiologists, and translating complex reports into plain language—to deliver a 22-minute, 9 full body MRI scan. Learn how this innovation is helping detect cancer in asymptomatic patients and why younger populations may benefit from early, proactive screening
From Interview #93
With Rajeev Ronanki
Rajeev Ronanki, CEO of Lyric, explores how the FDA’s evolving stance on artificial intelligence could reshape the future of drug development and healthcare delivery. In this compelling exchange, he unpacks the promise of Elsa—a tech-forward initiative by the FDA—and why it signals a paradigm shift from bureaucratic bottlenecks to data-driven decisions. Rajeev emphasizes how AI can accelerate therapeutic innovation, reduce inefficiencies, and make regulatory processes more transparent and predictive. His insights speak directly to healthcare executives, clinicians, and digital health innovators eager to understand federal AI adoption and its implications for clinical practice and pharma R&D.
From Interview #92
With Dr. Colleen Lyons
In this in-depth conversation, Dr. Colleen Lyons dives into the nuanced intersection of ethics and AI in healthcare, spotlighting overlooked risks and opportunities in today’s clinical AI tools. Drawing from her background at the FDA and in academia, she critiques the hollow nature of many ethical AI frameworks and calls for transparency and value-based governance over check-the-box compliance. The conversation covers the Belmont Report’s enduring relevance, AI's impact on autonomy and informed consent, and the systemic bias embedded in data. With regulatory landscapes still fragmented, Lyons argues for proactive, values-driven leadership to ensure AI adoption benefits patient care without unintended harms—particularly in vulnerable populations. If you're working at the frontline of AI implementation in provider systems or clinical operations, this episode is essential listening.
